Dinara Rose, MD
Internal Medicine · Baytown, TXNPI 1972942936
Payments from drug & device makers
Across 448 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- AstraZeneca$904
- Lilly USA, LLC$715
- Amgen$546
- Boehringer Ingelheim$533
- plus $3K from 34 others
What the payments were for
- Food & beverage$7,449100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 68 | $1,074 |
| Novo Nordisk | 62 | $1,035 |
| AstraZeneca | 56 | $904 |
| Lilly USA, LLC | 45 | $715 |
| Amgen(2 entities) | 31 | $546 |
| Boehringer Ingelheim | 33 | $533 |
| Johnson & Johnson | 31 | $479 |
| GSK | 20 | $381 |
| Merck | 27 | $357 |
| Bayer | 8 | $183 |
| Optinose US, Inc. | 8 | $145 |
| Pfizer | 5 | $85 |
| Exact Sciences | 4 | $83 |
| Sanofi-aventis U.S. LLC | 4 | $76 |
| Teva Pharmaceuticals USA, Inc. | 5 | $73 |
| Genentech USA, Inc. | 4 | $70 |
| Hologic Sales And Service, LLC | 2 | $67 |
| Astellas Pharma US Inc | 3 | $55 |
| Kowa Pharmaceuticals America, Inc. | 3 | $53 |
| Eisai Inc. | 3 | $48 |
| Dexcom, Inc. | 2 | $46 |
| Sanofi Pasteur Inc. | 2 | $42 |
| Novartis | 2 | $38 |
| Inspire Medical Systems, Inc. | 1 | $34 |
| Radius Health, Inc. | 2 | $33 |
| Organon | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Gilead | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Clarus Therapeutics Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Tolmar, Inc. | 1 | $18 |
| Abbott | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$7,463 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $73,120 |
| MounjaroTirzepatide | 30 | $45,670 |
| JardianceEmpagliflozin | 19 | $27,687 |
| EliquisApixaban | 15 | $17,964 |
| FarxigaDapagliflozin Propanediol | 12 | $9,821 |
| Colesevelam Hcl | 12 | $3,962 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $1,996 |
| Atorvastatin Calcium | 166 | $1,442 |
| Levothyroxine Sodium | 132 | $1,309 |
| Rosuvastatin Calcium | 94 | $1,210 |
| Gabapentin | 101 | $1,127 |
| Losartan Potassium | 110 | $1,107 |
| Olmesartan Medoxomil | 29 | $1,056 |
| Escitalopram Oxalate | 69 | $918 |
| Pantoprazole Sodium | 77 | $905 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,035 | $73,12059 claims |
| Lilly USA, LLCMounjaro | $715 | $45,67030 claims |
| Boehringer IngelheimJardiance | $533 | $27,68719 claims |
| PfizerEliquis | $85 | $17,96415 claims |
| AstraZenecaFarxiga | $904 | $9,82112 claims |
| AbbVieSynthroid | $1,074 | $66215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Baytown
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.